Education
About Us
Working with TipRanks
Follow Us
Acura Pharmaceuticals (ACUR)
OTHER OTC:ACUR
Total Valuation
Acura Pharmaceuticals has a market cap or net worth of $26.40K. The enterprise value is ―.
Market Cap$26.40K
Enterprise Value―
Share Statistics
Acura Pharmaceuticals has 66,001,785 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding66,001,785
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Acura Pharmaceuticals’s return on equity (ROE) is -6.06 and return on invested capital (ROIC) is -394.24%.
Return on Equity (ROE)-6.06
Return on Assets (ROA)-1.25
Return on Invested Capital (ROIC)-394.24%
Return on Capital Employed (ROCE)-3.52
Revenue Per Employee173.67K
Profits Per Employee-97.67K
Employee Count9
Asset Turnover1.82
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Acura Pharmaceuticals is ―. Acura Pharmaceuticals’s PEG ratio is 0.42.
PE Ratio―
PS Ratio18.17
PB Ratio159.55
Price to Fair Value159.55
Price to FCF-38.28
Price to Operating Cash Flow-0.02
PEG Ratio0.42
Income Statement
In the last 12 months, Acura Pharmaceuticals had revenue of 1.56M and earned -879.00K in profits. Earnings per share was -0.02.
Revenue1.56M
Gross Profit352.00K
Operating Income-1.21M
Pretax Income-879.00K
Net Income-879.00K
EBITDA-589.00K
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -742.00K and capital expenditures 0.00, giving a free cash flow of -742.00K billion.
Operating Cash Flow-742.00K
Free Cash Flow-742.00K
Free Cash Flow per Share-0.01
Dividends & Yields
Acura Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-9.43
52-Week Price Change-50.00%
50-Day Moving Average0.02
200-Day Moving Average―
Relative Strength Index (RSI)0.00
Average Volume (3m)260.00
Important Dates
Acura Pharmaceuticals upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Acura Pharmaceuticals as a current ratio of 0.72, with Debt / Equity ratio of 112.36%
Current Ratio0.72
Quick Ratio0.72
Debt to Market Cap<0.01
Net Debt to EBITDA-0.14
Interest Coverage Ratio-6.07
Taxes
In the past 12 months, Acura Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate-0.23
Enterprise Valuation
Acura Pharmaceuticals EV to EBITDA ratio is -48.36, with an EV/FCF ratio of -38.39.
EV to Sales18.22
EV to EBITDA-48.36
EV to Free Cash Flow-38.39
EV to Operating Cash Flow-38.39
Balance Sheet
Acura Pharmaceuticals has $65.00K in cash and marketable securities with $200.00K in debt, giving a net cash position of -$135.00K billion.
Cash & Marketable Securities$65.00K
Total Debt$200.00K
Net Cash-$135.00K
Net Cash Per Share>-$0.01
Tangible Book Value Per Share<$0.01
Margins
Gross margin is 94.24%, with operating margin of -77.67%, and net profit margin of -69.03%.
Gross Margin94.24%
Operating Margin-77.67%
Pretax Margin-56.24%
Net Profit Margin-69.03%
EBITDA Margin-37.68%
EBIT Margin-43.44%
Analyst Forecast
The average price target for Acura Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―